pharma · Acute Myeloid Leukemia · Narcolepsy · JAZZ
Jazz Pharmaceuticals Ireland Limited
Jazz Pharmaceuticals Ireland is a pharma organization headquartered in Dublin, IE. It trades on NYSE under ticker JAZZ. Primary therapeutic focus areas include Acute Myeloid Leukemia, Narcolepsy, Epilepsy, Acute Lymphobl
Phase 3 · small molecule · Fibromyalgia
Sodium oxybate (XYREM) is a small-molecule oral therapeutic developed by Jazz Pharmaceuticals Ireland Limited for fibromyalgia, currently in Phase 3 clinical development. The drug is already approved in both the United States and European Union for other indications, with XYREM approved in the EU as of May 12, 2025, un
Internal code 08-004
Sodium oxybate (XYREM) is a small-molecule oral therapeutic developed by Jazz Pharmaceuticals Ireland Limited for fibromyalgia, currently in Phase 3 clinical development. The drug is already approved in both the United States and European Union for other indications, with XYREM approved in the EU as of May 12, 2025, under marketing authorization holder UCB Pharma Ltd. Jazz's fibromyalgia program (internal code 08-004) completed Phase 3 testing as of August 19, 2011. Sodium oxybate is classified as a nervous system agent (ATC N07) and is administered orally. The program represents a label expansion strategy for an existing approved asset into a new therapeutic area with significant unmet medical need. Multiple generic and branded versions are available in the US market through sponsors including Amneal, Ascent Pharma, Avadel CNS, Hikma, and Ohm Labs, indicating mature market penetration. The fibromyalgia indication would represent a novel therapeutic application for this established molecule, potentially addressing a patient population with limited treatment options.
Fibromyalgia affects millions of patients globally and is characterized by chronic widespread musculoskeletal pain, fatigue, and cognitive dysfunction. Current treatment options are limited, with only a small number of FDA-approved medications (pregabalin, duloxetine, milnacipran), and many patients experience inadequate symptom control or intolerance to existing therapies. Sodium oxybate's mechanism in the central nervous system offers a potentially differentiated approach to fibromyalgia management. The competitive landscape for fibromyalgia therapeutics includes various nervous system agents, though the specific competitors listed in the database appear to address different neurological indications rather than fibromyalgia directly. Jazz Pharmaceuticals' strategy to expand XYREM into fibromyalgia leverages an already-approved, well-characterized molecule with established safety and manufacturing infrastructure, reducing development risk compared to de novo drug candidates. Commercial significance is substantial given the large fibromyalgia patient population and the chronic nature of the disease requiring long-term treatment. Successful approval would provide physicians and patients with an additional therapeutic option and potentially generate significant revenue from a label expansion with lower development costs than novel entities.
Sodium oxybate is a small-molecule oral therapeutic classified within the nervous system therapeutic class (ATC N07). The drug is administered orally and is marketed under the brand name XYREM. Sodium oxybate acts as a central nervous system agent, though the specific molecular target and detailed mechanism of action are not disclosed in available documentation. The compound represents a mature therapeutic with established pharmaceutical properties and manufacturing processes.
Also known as: fibromyalgia syndrome
A chronic disorder of unknown etiology characterized by pain, stiffness, and tenderness in the muscles of neck, shoulders, back, hips, arms, and legs. Other signs and symptoms include headaches, fatigue, sleep disturbances, and painful menstruation.
ClinicalTrials.gov lists 67 registered studies for Fibromyalgia Syndrome (AACT aggregate).
Phase breakdown: NA (53), PHASE2 (8), PHASE3 (4), PHASE4 (2)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0005546), Orphanet — fibromyalgia, NCT00222274, NCT00401830, NCT00436033, NCT00447083, NCT00464737, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 3 completion
Jazz Pharmaceuticals' fibromyalgia program (NCT00803023) completed Phase 3 testing.
The competitive landscape for fibromyalgia therapeutics includes multiple approved nervous system agents. The competitors identified in the database—including AMVUTTRA (Lacuna Pharma), AUSTEDO (Teva Pharma), DAYBU (Acadia Pharmaceuticals), ONPATTRO (Lacuna Pharma), B-PATCH (Indivior), NERVENTRA (Teva Pharma), NUEDEXTA (Amneal Pharma Europe), PHARMACOR RILUZOLE (Sanofi-aventis), PHARMACOR VARENICLINE (Alphapharm), VIOKAT (Soleno Therapeutics), VYNDAMAX (Pfizer), and QALSODY—represent a diverse therapeutic landscape addressing various neurological conditions. However, the specific positioning of these agents relative to fibromyalgia treatment is not detailed in available data. Sodium oxybate's competitive advantage lies in its established safety profile, oral administration route, and existing regulatory approvals, which reduce development and commercialization risk compared to novel entities. The availability of multiple generic manufacturers (Amneal, Ascent Pharma, Avadel CNS, Hikma, Ohm Labs) in the US market demonstrates market maturity and price competition, which may influence the commercial strategy for the fibromyalgia indication.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| AMVUTTRA | Lacuna Pharma Pty Ltd | — | approved |
| AUSTEDO | Teva Pharma GmbH | — | approved |
| DAYBU | Acadia Pharmaceuticals B.V. | — | approved |
| ONPATTRO | Lacuna Pharma Pty Ltd | — | approved |
| B-PATCH | Indivior Pty Ltd | — | approved |
| NERVENTRA | Teva Pharma GmbH | — | approved |
| NUEDEXTA | Amneal Pharma Europe Ltd | — | approved |
| PHARMACOR RILUZOLE | Sanofi-aventis Healthcare Pty Ltd | — | approved |
| PHARMACOR VARENICLINE | Alphapharm Pty Ltd | — | approved |
| VIOKAT | SOLENO THERAPEUTICS INC | — | approved |
| VYNDAMAX | Pfizer Australia Pty Ltd | — | approved |
| QALSODY | — | — | approved |
| PREGABALIN | — | Voltage-gated calcium channel modulator | Approved |
| MILNACIPRAN HYDROCHLORIDE | — | Serotonin transporter inhibitor | Approved |
| LEVOMILNACIPRAN HYDROCHLORIDE | — | Norepinephrine transporter inhibitor | Approved |
| DULOXETINE HYDROCHLORIDE | — | Serotonin transporter inhibitor | Approved |
| TRAMADOL | — | Mu opioid receptor agonist | Phase 3 |
| SOMATROPIN | — | Growth hormone receptor agonist | Phase 3 |
| SODIUM OXYBATE | — | GABA-B receptor agonist | Phase 3 |
| REBOXETINE | — | Norepinephrine transporter inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Sodium oxybate (XYREM) holds established regulatory approvals in major markets:
The fibromyalgia indication represents a label expansion for an already-approved molecule. Regulatory pathway and approval status for the fibromyalgia indication are not yet disclosed in available documentation.
Sodium oxybate is approved in the US and EU for certain indications and is currently in Phase 3 development for fibromyalgia, a chronic pain condition characterized by widespread musculoskeletal pain and fatigue.
Approval status for the fibromyalgia indication is not yet disclosed. The Phase 3 trial completed in August 2011, but regulatory decisions have not been publicly announced.
Jazz Pharmaceuticals Ireland Limited sponsors the fibromyalgia program. Multiple manufacturers produce approved versions in the US, including Amneal, Ascent Pharma, Avadel CNS, Hikma, and Ohm Labs. UCB Pharma Ltd holds the EU marketing authorization.
Sodium oxybate is a central nervous system agent classified as a nervous system therapeutic (ATC N07). The specific molecular mechanism of action is not disclosed in available documentation.
Sodium oxybate is administered orally as a small-molecule therapeutic.
Phase 3 trial NCT00803023 completed in August 2011. Detailed results and primary endpoints are not yet reported in available documentation.
Sodium oxybate received FDA approval via NDA021196 and NDA214755. Specific approval dates are not disclosed in available documentation.
Sodium oxybate (XYREM) was approved in the EU on May 12, 2025, under EMEA/H/C/000593, with UCB Pharma Ltd as the marketing authorization holder.
The fibromyalgia program is identified as 08-004 in Jazz Pharmaceuticals' internal coding system.
The program is in Phase 3, with the most recent disclosed milestone being trial completion on August 19, 2011.
Yes, multiple generic versions are available in the US market from Amneal, Ascent Pharma, Avadel CNS, Hikma, and Ohm Labs under various ANDA approvals.
Sodium oxybate is classified as a nervous system agent (ATC N07) and is administered orally.
No partner is disclosed for the fibromyalgia development program; Jazz Pharmaceuticals Ireland Limited is listed as the sole sponsor.
Fibromyalgia affects millions of patients with limited approved treatment options; many patients experience inadequate symptom control or intolerance to existing therapies, creating significant unmet need.
Approved nervous system agents in the competitive landscape include AUSTEDO, DAYBU, NUEDEXTA, and others, though specific fibromyalgia positioning is not detailed in available data.
Projected peak sales figures are not yet disclosed in available documentation.
Sodium Oxybate → Drug → Target → Indication → Company → Trials → Competitors
Jazz Pharmaceuticals' fibromyalgia program represents a label expansion strategy for an established molecule with proven regulatory and commercial track record. Completion of Phase 3 testing in August 2011 suggests the program advanced toward regulatory submission, though current approval status for the fibromyalgia indication is not disclosed. Key strategic implications include: (1) leveraging existing safety and efficacy data to reduce development timelines and costs; (2) addressing an underserved patient population with limited pharmacological options; (3) potential for rapid commercialization given established manufacturing and distribution infrastructure. The presence of multiple generic competitors in the US market indicates mature market dynamics for the base molecule, which may influence pricing and market positioning for the fibromyalgia indication. Future catalysts include regulatory decision announcements, label expansion approvals, and clinical data publication. The program's status as of the latest disclosed milestone (August 2011) suggests potential regulatory submissions may have occurred in subsequent years, though specific approval timelines and outcomes are not yet disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.